Tirzepatide
Tirzepatide (dual GIP/GLP-1 receptor agonist peptide; LY3298176) · ≥98% (HPLC)
Tirzepatide is a synthetic 39-residue lipidated dual GIP/GLP-1 receptor agonist peptide supplied as a characterized reference material for in-vitro receptor and analytical research. For Research Use Only. Not for human or veterinary use.
- Why researchers study it
- Studied in vitro as a single-molecule probe of co-agonism at two distinct incretin receptors (GIPR and GLP-1R), making it a frequent reference point in receptor-pharmacology and peptide-engineering literature.
- Mechanism themes in research
- Dual GIP receptor (GIPR) and GLP-1 receptor (GLP-1R) agonismIncretin-receptor signaling and cAMP / G-protein pathway activation in vitroFatty-diacid lipidation conferring albumin binding and extended in-vitro stabilityAib substitutions imparting peptidase resistance
- What the evidence does not establish
- Published references are in-vitro or pre-clinical and describe research context only. They do not establish safety, efficacy, or any outcome in humans or animals, and Helix makes no such claims.
- Quality markers
- ≥98% (HPLC)MS identityLot COACold-chain
Tirzepatide (LY3298176) is a synthetic 39-amino-acid linear peptide engineered as a single-molecule dual agonist of the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the glucagon-like peptide-1 receptor (GLP-1R). Its sequence is derived from the native GIP backbone and incorporates two 2-aminoisobutyric acid (Aib) substitutions, a C-terminal amide, and a C20 fatty-diacid moiety attached to the Lys20 side chain through a γ-glutamate / di-AEEA linker. It is offered strictly as a characterized reference material for in-vitro and analytical research. For Research Use Only — not for human or veterinary use.
Molecular identity
A 39-residue linear peptide with the molecular formula C₂₂₅H₃₄₈N₄₈O₆₈ and a monoisotopic/average molecular weight of approximately 4813.5 g/mol (CAS 2023788-19-2; PubChem CID 156588324). The sequence carries 2-aminoisobutyric acid (Aib) at positions 2 and 13 and a C-terminal amide.
Structural features
The Lys20 side chain is conjugated to a 1,20-eicosanedioic (C20) fatty diacid through a glutamic-acid spacer and two (2-(2-aminoethoxy)ethoxy)acetic acid (AEEA) units. This lipidation is discussed in the literature as the basis for albumin association, while the Aib substitutions are associated with resistance to dipeptidyl-peptidase cleavage in characterization studies.
| Full name | Tirzepatide (dual GIP/GLP-1 receptor agonist peptide; LY3298176) |
| Research theme | Metabolic signaling |
| CAS number | 2023788-19-2 |
| Molecular formula | C₂₂₅H₃₄₈N₄₈O₆₈ |
| Molecular weight | 4813.5 g/mol |
| Purity | ≥98% (HPLC) |
| Physical form | Lyophilized powder |
| Storage | −20 °C, desiccated, protected from light |
Sequence
Reported research areas
- Incretin receptor (GIPR / GLP-1R) signaling assays
- Peptide structure-activity and lipidation studies
- Comparative receptor co-agonism pharmacology
- Analytical method development and reference standardization
Credible sources
- PubChem CID 156588324 — Tirzepatide
- PubChem search — Tirzepatide
- PubMed — Tirzepatide GIP/GLP-1 literature
COA with every lot
Each Tirzepatide lot is characterized by reversed-phase HPLC for purity and by mass spectrometry for identity, then documented in a per-lot Certificate of Analysis. Unique lot numbers tie the vial back to its synthesis batch and analytical data.
- RP-HPLC purity result (≥98% (HPLC))
- Mass-spectrometry identity confirmation
- Appearance, molecular weight, and storage
- Lot number and testing status
Specimen Certificate of Analysis
| Product | Tirzepatide (reference) |
| Lot | HXR-2406-100 |
| Purity (RP-HPLC) | 98%+ |
| Identity (MS) | Confirmed · 4813.5 g/mol |
| Appearance | Lyophilized powder |
| Storage | −20 °C, desiccated |
Representative document. Each lot has its own COA — these are quality documents, not medical claims.